295 related articles for article (PubMed ID: 34354386)
1. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma.
Pongas G; Cheson B
Blood Lymphat Cancer; 2021; 11():55-66. PubMed ID: 34354386
[TBL] [Abstract][Full Text] [Related]
2. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
Cohen JA; Ghobadi A
Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
[TBL] [Abstract][Full Text] [Related]
3. Advancements in the Management of Follicular Lymphoma: A Comprehensive Review.
Merryman R; Mehtap Ö; LaCasce A
Turk J Haematol; 2024 May; 41(2):69-82. PubMed ID: 38660754
[TBL] [Abstract][Full Text] [Related]
4. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
Kambhampati S; Shouse G; Danilov AV
Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
6. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
7. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma.
Yaniv B; Tanenbaum B; Kazakova V; Patel SA
Leuk Res; 2024 Jul; 142():107519. PubMed ID: 38761562
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
9. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
Locke FL; Go WY; Neelapu SS
JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
[TBL] [Abstract][Full Text] [Related]
10. Advances in chimeric antigen receptor T cells.
Beyar-Katz O; Gill S
Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186
[TBL] [Abstract][Full Text] [Related]
11. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.
Hanel W; Epperla N
J Hematol Oncol; 2021 Jun; 14(1):104. PubMed ID: 34193230
[TBL] [Abstract][Full Text] [Related]
12. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.
Jain MD; Bachmeier CA; Phuoc VH; Chavez JC
Ther Clin Risk Manag; 2018; 14():1007-1017. PubMed ID: 29910620
[TBL] [Abstract][Full Text] [Related]
13. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
Mol Ther; 2024 May; ():. PubMed ID: 38822527
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Makita S; Imaizumi K; Kurosawa S; Tobinai K
Drugs Context; 2019; 8():212567. PubMed ID: 30815024
[TBL] [Abstract][Full Text] [Related]
16. The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma.
Sandoval-Sus J; Chavez JC
Ther Adv Hematol; 2021; 12():20406207211017788. PubMed ID: 34104371
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.
Ahmed G; Furqan F; Nasrollahi E; Hamadani M
Expert Rev Anticancer Ther; 2024 Jun; ():1-11. PubMed ID: 38809821
[TBL] [Abstract][Full Text] [Related]
19. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]